BLCO at a glance
Bausch & Lomb Corp (BLCO, SEC CIK 1860742) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as August 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bausch & Lomb Corp (BLCO) reported revenue of $5.1 billion (up 6.5% from FY2024) and a net loss of $360.0 million. Diluted EPS was -$1.02.
- As of June 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Bausch & Lomb Corp (BLCO) shares worth $196.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Munsch Frederick on August 10, 2026 of 52,900 shares at $16.78 per share.
- In the last 90 days, BLCO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.2M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.1B
- +6.5% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$1.2M
- 13F holders
- 17 funds
- $196.4M · −1 vs prior quarter
- Latest 10-Q
- Jul 29, 2026
- Quarterly report
SignalX for BLCO
Don't miss the next BLCO filing
- Alerts as it files. A push when BLCO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BLCO, by share count.
- Ask anything. An AI agent that reads every BLCO filing and answers with sources.
BLCO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Trebbi Barbara | A | Aug 12, 2026 | 11,776 | - |
| Chersi Robert J | A | Aug 12, 2026 | 11,776 | - |
| PAUL LAURENCE E | A | Aug 12, 2026 | 11,776 | - |
| Munsch Frederick | Sell | Aug 10, 2026 | 52,900 | $16.78 |
| VON ESCHENBACH ANDREW C. | Sell | Aug 7, 2026 | 6,059 | $16.58 |
| VON ESCHENBACH ANDREW C. | Sell | Aug 6, 2026 | 12,500 | $16.50 |
| Munsch Frederick | A | Aug 5, 2026 | 9,091 | - |
| Hashad Yehia | A | Aug 5, 2026 | 20,973 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.8B | $5.1B |
| Operating Income | - | $162.0M | $113.0M |
| Net Income | -$260.0M | -$317.0M | -$360.0M |
| Op. Margin | - | 3.4% | 2.2% |
| Net Margin | - | -6.6% | -7.1% |
| Balance Sheet | |||
| Total Assets | $13.4B | $13.5B | $14.0B |
| Equity | - | $6.5B | $6.4B |
| ROE | - | -4.9% | -5.6% |
| Per Share | |||
| EPS | $-0.74 | $-0.90 | $-1.02 |
| Cash Flow | |||
| Operating CF | - | $232.0M | $283.0M |
| CapEx | $181.0M | $291.0M | $349.0M |
Source: XBRL data in Bausch & Lomb Corp (BLCO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BLCO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 17 | $196.4M |
| Q1 2026 | 18 | $166.7M |
| Q4 2025 | 16 | $194.6M |
| Q3 2025 | 15 | $169.5M |
| Q2 2025 | 17 | $131.7M |
| Q1 2025 | 15 | $118.0M |
| Q4 2024 | 13 | $146.4M |
| Q3 2024 | 10 | $142.3M |
- T. Rowe Price Group+936.6K (+76%)
- Citadel Advisors LLC+282.5K (+40%)
- D.E. Shaw & Co+171.9K (+5%)
- Goldman Sachs Group+127.3K (+43%)
- JPMorgan Chase & Co+120.5K (+80359%)
- Morgan Stanley−142.6K (-17%)
- Millennium Management−126.4K (-42%)
- Bank of America Corp−17.6K (-27%)
- Ameriprise Financial−3.2K (-3%)
- Invesco Ltd−463 (-4%)
- Third Point LLC+85.0K
- FMR LLC (Fidelity)−114.3K
- Raymond James Financial−24.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 121 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- COO · Cooper Companies (The)Ophthalmic Goods
- EYE · National Vision Holdings, Inc.Ophthalmic Goods
- RXST · RxSight, Inc.Ophthalmic Goods
- STAA · STAAR SURGICAL COOphthalmic Goods
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
BLCO SEC filings: frequently asked questions
Are BLCO insiders buying or selling?
In the last 90 days, Bausch & Lomb Corp (BLCO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BLCO stock?
As of June 30, 2026, the largest Bausch & Lomb Corp (BLCO) holders among the 13F filers tracked by SignalX were Carl Icahn ($58.0 million), D.E. Shaw & Co ($55.0 million), T. Rowe Price Group ($35.8 million), Citadel Advisors LLC ($16.4 million), Morgan Stanley ($11.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BLCO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bausch & Lomb Corp (BLCO) reported revenue of $5.1 billion (up 6.5% from FY2024) and a net loss of $360.0 million. Diluted EPS was -$1.02. The figures come from the XBRL data in the 10-K.
What are the latest BLCO SEC filings?
Bausch & Lomb Corp (BLCO) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on August 14, 2026.
What is BLCO's SEC CIK number?
Bausch & Lomb Corp (BLCO)'s SEC Central Index Key (CIK) is 1860742. EDGAR lists every BLCO filing under that number.
Ask anything about BLCO
The research agent reads BLCO's filings, financials, insider trades and 13F holders, then answers with sources.